Kane Biotech Inc. (KNBIF)
| Market Cap | 4.64M -59.4% |
| Revenue (ttm) | 412.72K -71.4% |
| Net Income | -2.34M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,250 |
| Average Volume | 40,301 |
| Open | 0.0270 |
| Previous Close | 0.0262 |
| Day's Range | 0.0261 - 0.0270 |
| 52-Week Range | 0.0210 - 0.0720 |
| Beta | 0.08 |
| RSI | 45.90 |
| Earnings Date | Apr 28, 2026 |
About Kane Biotech
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio inclu... [Read more]
News
Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article authored b...
Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
WINNIPEG, Manitoba, March 10, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (Kane or the Company), transforming wound care with three FDA 510(k) cleared and two Health Canada approved formats, is pleased...
Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve® Antimicrobial wound gel in the In...
Kane Biotech Expands Commercial Activities in the United States
WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has signed non-exclusive distribution/sales agreements for...
Kane Biotech Secures FDA 510(k) Clearance For Revyve Antimicrobial Skin And Wound Cleanser
(RTTNews) - Kane Biotech Inc. (KNBIF) announced that the U.S. FDA has granted 510(k) clearance for its revyve Antimicrobial Skin and Wound Cleanser, marking a key regulatory milestone for the company'...
Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser
Company expands ISO 13485/MDSAP Certification to support growing wound care portfolio Company expands ISO 13485/MDSAP Certification to support growing wound care portfolio
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
Not for distribution to U.S. news wire services or dissemination in the United States Not for distribution to U.S. news wire services or dissemination in the United States
Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting
WINNIPEG, Manitoba, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) announces that it presented new clinical and scientific data at the Innova...
Kane Biotech Announces Third Quarter 2025 Financial Results
WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results.
Kane Biotech Announces New Private Placement Offering
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the...
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) today announced new clinical and pre-clinical data demonstrating the performance of its ...
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser
WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has completed a U.S. Food and Drug Administration (“FDA”)...
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray
WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) today announces that it has enrolled 28 participants in its revyve® Antimicrobial Wound ...
Kane Biotech Announces Second Quarter 2025 Financial Results
WINNIPEG, Manitoba, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its second quarter 2025 financial results.
Kane Biotech to Present at Advanced Wound Care Summit USA
WINNIPEG, Manitoba, July 14, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) announces today that Kane Biotech's Interim Chief Executive Officer, Dr. Robert Huizinga...
Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, June 26, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotec...
Kane Biotech Provides Further Corporate Update
WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) provides updates on its reorganizational phase.
Kane Biotech Announces First Quarter 2025 Financial Results
WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its first quarter 2025 financial results.
Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 05, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Ka...
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year 2024 financ...
Kane Biotech Announces New Agreement with Outside the Box Capital Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba,, April 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech” ...
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to moderate Acne Vulgaris Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to m...
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel
Strategic Partnership Expands Access to Innovative Wound Care Solution Across Canada Strategic Partnership Expands Access to Innovative Wound Care Solution Across Canada
Kane Biotech Announces Second and Final Closing of Private Placement Offering
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “K...
Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “K...